You Be the Coder:
Confirm Non-ESRD Use for J0881
Published on Tue Dec 15, 2015
Question: A patient who is on chemotherapy treatment for lymphoma, presents for a weekly injection of darbepoetin alfa. The patient was documented to receive 500 mcg of Aranesp subcutaneously. How can we report this service? Answer: From the description provided, it is evident that the patient reports for darbepoetin alfa injection. Darbepoetin alfa (Aranesp®) is an erythrocyte stimulating agent and [...]